Literature DB >> 20143386

3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI.

Liana G Apostolova1, Paul M Thompson, Amity E Green, Kristy S Hwang, Charleen Zoumalan, Clifford R Jack, Danielle J Harvey, Ronald C Petersen, Leon J Thal, Paul S Aisen, Arthur W Toga, Jeffrey L Cummings, Charles S Decarli.   

Abstract

We applied the hippocampal radial atrophy mapping technique to the baseline and follow-up magnetic resonance image data of 169 amnestic mild cognitive impairment (MCI) participants in the imaging arm of the Alzheimer's Disease Cooperative Study MCI Donepezil/Vitamin E trial. Sixty percent of the subjects with none to mild hippocampal atrophy rated with the visual medial temporal atrophy rating scale (MTA score < 2) and 33.8% of the subjects with moderate to severe (MTA > or = 2) hippocampal atrophy converted to Alzheimer's disease (AD) during 3-year follow-up. MTA > or = 2 showed a trend for greater left sided hippocampal atrophy versus MTA < 2 groups at baseline (P(corrected) = 0.08). Higher MTA scores were associated with progressive atrophy of the subiculum and the CA1-3 subregions. The MTA < 2 group demonstrated significant bilateral atrophy progression at follow-up (left P(corrected) = 0.008; right P(corrected) = 0.05). Relative to MTA < 2 nonconverters, MTA < 2 converters showed further involvement of the subiculum and CA1 and additional involvement of CA2-3 at follow-up. Right CA1 atrophy was significantly associated with conversion to dementia (for 1 mm greater right CA1 radial distance subjects had 50% reduced hazard for conversion). Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20143386      PMCID: PMC2938765          DOI: 10.1002/hbm.20905

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  38 in total

1.  Magnetic resonance image tissue classification using a partial volume model.

Authors:  D W Shattuck; S R Sandor-Leahy; K A Schaper; D A Rottenberg; R M Leahy
Journal:  Neuroimage       Date:  2001-05       Impact factor: 6.556

2.  3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease.

Authors:  Liana G Apostolova; Ivo D Dinov; Rebecca A Dutton; Kiralee M Hayashi; Arthur W Toga; Jeffrey L Cummings; Paul M Thompson
Journal:  Brain       Date:  2006-10-03       Impact factor: 13.501

3.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.

Authors:  Gregory A Jicha; Joseph E Parisi; Dennis W Dickson; Kris Johnson; Ruth Cha; Robert J Ivnik; Eric G Tangalos; Bradley F Boeve; David S Knopman; Heiko Braak; Ronald C Petersen
Journal:  Arch Neurol       Date:  2006-05

4.  Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.

Authors:  Charles DeCarli; Giovanni B Frisoni; Christopher M Clark; Danielle Harvey; Michael Grundman; Ronald C Petersen; Leon J Thal; Shelia Jin; Clifford R Jack; Philip Scheltens
Journal:  Arch Neurol       Date:  2007-01

5.  Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability.

Authors:  P Scheltens; L J Launer; F Barkhof; H C Weinstein; W A van Gool
Journal:  J Neurol       Date:  1995-09       Impact factor: 4.849

6.  Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type.

Authors:  J G Csernansky; L Wang; S Joshi; J P Miller; M Gado; D Kido; D McKeel; J C Morris; M I Miller
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

7.  Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.

Authors:  Esther S C Korf; Lars-Olof Wahlund; Pieter Jelle Visser; Philip Scheltens
Journal:  Neurology       Date:  2004-07-13       Impact factor: 9.910

8.  Atrophy of hippocampal formation subdivisions correlates with stage and duration of Alzheimer disease.

Authors:  M Bobinski; J Wegiel; H M Wisniewski; M Tarnawski; B Reisberg; B Mlodzik; M J de Leon; D C Miller
Journal:  Dementia       Date:  1995 Jul-Aug

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 10.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Steven T Dekosky; Pascale Barberger-Gateau; Jeffrey Cummings; André Delacourte; Douglas Galasko; Serge Gauthier; Gregory Jicha; Kenichi Meguro; John O'brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal:  Lancet Neurol       Date:  2007-08       Impact factor: 44.182

View more
  57 in total

1.  Mnemonic strategy training improves memory for object location associations in both healthy elderly and patients with amnestic mild cognitive impairment: a randomized, single-blind study.

Authors:  Benjamin M Hampstead; Krish Sathian; Pamela A Phillips; Akshay Amaraneni; William R Delaune; Anthony Y Stringer
Journal:  Neuropsychology       Date:  2012-03-12       Impact factor: 3.295

2.  In vivo analysis of hippocampal subfield atrophy in mild cognitive impairment via semi-automatic segmentation of T2-weighted MRI.

Authors:  John Pluta; Paul Yushkevich; Sandhitsu Das; David Wolk
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease.

Authors:  Liana G Apostolova; Kristy S Hwang; Luis D Medina; Amity E Green; Meredith N Braskie; Rebecca A Dutton; Jeffrey Lai; Daniel H Geschwind; Jeffrey L Cummings; Paul M Thompson; John M Ringman
Journal:  Dement Geriatr Cogn Disord       Date:  2011-09-23       Impact factor: 2.959

4.  Mild cognitive impairment: differential atrophy in the hippocampal subfields.

Authors:  B J Hanseeuw; K Van Leemput; M Kavec; C Grandin; X Seron; A Ivanoiu
Journal:  AJNR Am J Neuroradiol       Date:  2011-08-11       Impact factor: 3.825

5.  Pattern separation and pattern completion in Alzheimer's disease: evidence of rapid forgetting in amnestic mild cognitive impairment.

Authors:  Brandon A Ally; Erin P Hussey; Philip C Ko; Robert J Molitor
Journal:  Hippocampus       Date:  2013-08-14       Impact factor: 3.899

Review 6.  The clinical value of large neuroimaging data sets in Alzheimer's disease.

Authors:  Arthur W Toga
Journal:  Neuroimaging Clin N Am       Date:  2011-12-17       Impact factor: 2.264

7.  MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease.

Authors:  D P Devanand; Ravi Bansal; Jun Liu; Xuejun Hao; Gnanavalli Pradhaban; Bradley S Peterson
Journal:  Neuroimage       Date:  2012-01-25       Impact factor: 6.556

8.  Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls.

Authors:  Jonathan H Morra; Zhuowen Tu; Liana G Apostolova; Amity E Green; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Arthur W Toga; Clifford R Jack; Norbert Schuff; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2008-11-08       Impact factor: 6.556

9.  Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls.

Authors:  Yi-Yu Chou; Natasha Leporé; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Xue Hua; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Arthur W Toga; Paul M Thompson
Journal:  Neuroimage       Date:  2009-02-21       Impact factor: 6.556

10.  Surface fluid registration of conformal representation: application to detect disease burden and genetic influence on hippocampus.

Authors:  Jie Shi; Paul M Thompson; Boris Gutman; Yalin Wang
Journal:  Neuroimage       Date:  2013-04-13       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.